A Nanocarrier technology platform for therapeutic siRNA and drug deliveryTumors arise and grow as a result of genetic changes that i. e. generate oncogenic proteins. The concept of personalized cancer therapy was developed to attack these factors specifically. However, intervention by chemical inhibitors harbors the risk of bypass reactions and the development of resistance mechanisms. We therefore applied the principle of RNA interference (RNAi)-mediated inhibition of various oncogenes as a therapeutic option in tumor treatment.The therapeutic use of RNAi has always been compromised by the missing delivery of the active substance siRNA to the target cell. For this purpose, we have developed a principle of tumor cell-specific application of siRNAs using target cell-specific surface receptor antibodies decorating an electrostatically self-assembling nanocarrier for the complexation and transport of the siRNA. The siRNAs are directed against highly specific oncogenes, and a combination of different siRNAs is also applicable, as well as the integration of small molecular drugs into the nanocarriers. Here, the use of an oncogene-specific siRNA and the choice of a tumor-specific surface receptor offers a double level of specificity and focuses the siRNA treatment on the tumor cells. The universal carrier protamine has been known from clinical use for decades and can be used in all applications.Publications:Bäumer, N. et al.: Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol. 15, 171 (2022). https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01390-5Bäumer, N. et al.: Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene 41, 2210–2224 (2022). https://www.nature.com/articles/s41388-022-02241-wFaust, A. et al.: Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew Chem Int Ed Engl. 2022: e202109769. https://onlinelibrary.wiley.com/doi/full/10.1002/anie.202109769Full publication list:https://www.ncbi.nlm.nih.gov/myncbi/sebastian.baumer.1/bibliography/public/